Plant-based Biologics and Expression Systems Market, 2022-2035

Plant-based Biologics and Expression Systems Market, 2022-2035

A significant rise in the popularity of biologics has been observed over the years. The demand for such treatment modalities further witnessed a surge post the onset of the COVID-19 pandemic. At present, about 85% of the drug candidates are produced using mammalian cell cultures. However, such systems are associated with a number of challenges; these include risk of introducing pathogens, concerns related to scale-up, decrease in productivity and rise in byproduct formation. , It is also worth highlighting that research indicates that the existing mammalian cell capacities are likely to fulfill only 50% of the inflated demand (due to COVID-19) for biologics. In this context, owing to some major advances in synthetic organic chemistry, plant based expression systems have emerged as a promising alternative for the development of biologics. It is worth mentioning that plant-host engineering allows the production of proteins with distinct and uniform post-translational modifications, allowing the development of biologics, which demonstrate higher effectiveness, as compared to those produced using other protein expression systems, such as mammalian or yeast-based cell cultures. Plant-based biologics are safer, as they pose negligible risk of introducing human and animal pathogens in the therapy candidates. Additionally, plant molecular farming has the ability to facilitate rapid (4-8 weeks) plant-based biologics manufacturing at a large scale (several grams), as well as to meet the emergency demands (as observed in the case of COVID-19 pandemic). Moreover, the running costs of a GMP plant-based manufacturing facility are reported to be 25% less than those using other expression systems.

Given the aforementioned factors, pharmaceutical players are actively adopting plant-based expression systems for the production of various recombinant proteins. A wide range of vaccine candidates, plant-based enzymes, therapeutic proteins (including monoclonal antibodies) and nutritional proteins have also been produced via transgenic and transient expression in entire plants or plant cell cultures. Currently, close to 50 plant-based therapies have been developed / are being evaluated and more than 35 plant-based expression system providers are actively offering their proprietary technologies to drug developers. Multiple partnerships between industry and non-industry stakeholders, focused on the development of plant-based therapies, have been established. Driven by increasing prevalence of disease indications, growing demand for biologics, the ongoing efforts being carried out to advance the development of such products, as well as further optimize the associated technologies, the global plant-based biologics market is likely to grow at a healthy rate, in the foreseen future.

The “Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Service (Research and Development, Manufacturing, Fill / Finish and Others), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp), and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of plant-based therapies in the pharmaceutical industry, over the next 13 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

A detailed overview of the current market landscape of plant-based expression system providers, including information on some relevant parameters such as the type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product (antibodies (unspecified), biosimilars, cell therapies, gene therapies, monoclonal antibodies, proteins (unspecified), vaccines and others), type of service (R&D, manufacturing, fill / finish, and others) and type of expression system (transient and stable). Additionally, it highlights information on plant-based expression system providers, including details related to their respective year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary technologies.

A detailed overview of the current market landscape of plant-based biologics, including information on their status of development (marketed, clinical and preclinical), target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher Disease, liver cirrhosis, influenza, and peanut allergy), therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others) and type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). Additionally, it highlights the developers of these novel therapeutics, including details on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.

Elaborate profiles of key players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to its technology portfolio, recent developments, and an informed future outlook.

An analysis of the recent partnerships and collaborations that have been inked between various stakeholders in the domain, during the period between 2017 and 2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions and others.

An insightful company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in offering plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). It also includes a benchmarking analysis of systems providers based on their portfolio strength and partnership activity.

An insightful publication analysis, which includes analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. Additionally, it features key trends observed across the aforementioned publications, including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and key timelines. Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of article, grant support, journal impact factor and timeline of publications.

One of the key objectives of the report was to estimate the existing size and the future opportunity associated with the plant-based biologics and expression systems market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates, expected pricing and R&D expenditure, we have provided informed estimates on the financial evolution of the market for the period 2022-2035. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines and others [B] type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco and wheat germ), [C] type of service (research and development, manufacturing, fill / finish and others), [D] type of expression system (stable expression system and transient expression system) [E] target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy) [F] therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others) [G] drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and [H] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports

Investor presentations

SEC filings

Industry databases

News releases from company websites

Government policy documents

Industry analysts’ views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Who are the key players engaged in providing plant-based expression systems?

What are the key plant sources utilized by drug developers to manufacture plant-based biologics?

Which are the key therapeutic areas for which plant-based biologics are being developed?

What are the different proprietary technologies of plant-based expression system providers?

What type of partnership models are most commonly adopted by stakeholders engaged in this domain?

What is the relative competitiveness of different plant-based expression system providers?

What is the evolving trend related to the focus of publications related to plant-based biologics?

How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of plant-based biologics and expression systems market and its likely evolution in the coming future.

Chapter 3 is an introductory chapter that highlights important concepts related to plant-based expression system providers. The chapter features information on classification of plant-based expression platforms and their associated advantages. Additionally, it includes a discussion on the commonly used plant-based bioproduction systems and mechanism of plant expression platforms. Further, it features details related to several recent developments observed in this domain.

Chapter 4 includes information on more than 35 plant-based expression system providers. It features a detailed analysis on current market landscape of plant-based expression system providers, including type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product, type of service (R&D, manufacturing, fill / finish, and others) and type of expression system (transient and stable). Additionally, the chapter features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary technologies.

Chapter 5 includes information on more than 45 plant-based biologics. It features a detailed analysis on current market landscape of plant-based biologics, including information on status of development (marketed, clinical and preclinical), target disease indication, therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others), type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). The chapter also features developers’ landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary drug candidates.

Chapter 6 features elaborate profiles of the prominent players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to technology portfolio, recent developments, and an informed future outlook.

Chapter 7 presents an analysis on recent collaborations and partnerships that have been inked by several stakeholders in this domain, during the period 2017-2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions, and others.

Chapter 8 presents a detailed company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in the domain of plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). In addition, it features a spider web representation illustrating benchmarking of players based on portfolio strength and partnership activity of key players.

Chapter 9 presents an insightful analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. It also features, key trends observed across the aforementioned publications including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and analysis based on timeline. Further, the chapter also highlights a multivariate publication attractiveness analysis based on various parameters such as type of article, grant support, journal impact factor and timeline of publications.

Chapter 10 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with plant-based expression system market, during the period 2022-2035. Additionally, the chapter provides the likely distribution of the current and forecasted opportunity based on type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines, and others). type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of service (research and development, manufacturing, fill / finish, and others), type of expression system (stable expression system and transient expression system), region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 11 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with the plant-based biologics market, during the period 2022-2035. The chapter also provides the likely distribution of the current and forecasted opportunity based on type of target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy), type of therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others), drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and region (North America, Europe, Asia and Rest of the World).

Chapter 12 summarizes the entire report. It represents key takeaways and summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 14 is an appendix, which provides tabulated data and numbers for all figures provided in the report.

Chapter 15 is an appendix, which comprises of the list of companies and organizations mentioned in the report.